Holen Sie sich die Stockscreener-App
1.60
1.27%
0.02
Schlusskurs vom Vortag:
$1.58
Offen:
$1.58
24-Stunden-Volumen:
581.47K
Relative Volume:
0.49
Marktkapitalisierung:
$107.78M
Einnahmen:
$488.00K
Nettoeinkommen (Verlust:
$-41.44M
KGV:
-1.7204
EPS:
-0.93
Netto-Cashflow:
$-31.47M
1W Leistung:
+0.00%
1M Leistung:
-44.25%
6M Leistung:
-34.69%
1J Leistung:
-61.45%
1-Tages-Spanne:
$1.58
$1.68
1-Wochen-Bereich:
$1.53
$1.68
52-Wochen-Spanne:
$1.48
$4.99
Cardiff Oncology Inc Stock (CRDF) Company Profile
Firmenname
Cardiff Oncology Inc
Sektor
Branche
Telefon
858-952-7570
Adresse
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
1.60 | 106.43M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Eingeleitet | Noble Capital Markets | Outperform |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2025-06-24 | Eingeleitet | Jefferies | Hold |
| 2024-09-06 | Eingeleitet | Craig Hallum | Buy |
| 2022-01-05 | Eingeleitet | William Blair | Outperform |
| 2021-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-08-09 | Fortgesetzt | Maxim Group | Buy |
| 2020-10-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-08 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Cardiff Oncology Inc Aktie (CRDF) Neueste Nachrichten
Can Cardiff Oncology Inc. stock reach $100 price targetMarket Activity Recap & Safe Entry Trade Signal Reports - mfd.ru
Will Cardiff Oncology Inc. stock outperform tech sector in 2025Weekly Stock Report & Free Community Supported Trade Ideas - mfd.ru
Why Cardiff Oncology Inc. (XE7C) stock could be next leaderJuly 2025 Fed Impact & Weekly Top Performers Watchlists - mfd.ru
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
FY2027 Earnings Estimate for CRDF Issued By Zacks Small Cap - MarketBeat
CRDF: New CEO Presents Phase II Readout - Yahoo Finance
Leadership Turmoil Clouds Clinical Progress at Cardiff Oncology - AD HOC NEWS
Ideas Watch: Is Cardiff Oncology Inc likely to announce a buybackWeekly Gains Summary & Safe Entry Trade Reports - baoquankhu1.vn
Cardiff Oncology (CRDF) Is Down 43.9% After Advancing Onvansertib And Reshuffling Leadership Team - Yahoo Finance
Cardiff Oncology Faces Turbulence Amid Leadership Changes - StocksToTrade
CRDF: HC Wainwright & Co. Reiterates Buy Rating with $10 Price T - GuruFocus
H.C. Wainwright reiterates Buy rating on Cardiff Oncology stock at $10 - Investing.com Canada
Cardiff Oncology (CRDF) Stock Drop Presents New Investment Oppor - GuruFocus
Why Did Cardiff Oncology Stock Plunge On Tuesday?Cardiff Oncology (NASDAQ:CRDF) - Benzinga
Investors Buy High Volume of Cardiff Oncology Call Options (NASDAQ:CRDF) - Defense World
Cardiff Oncology appoints interim CEO amid leadership transition By Investing.com - Investing.com India
Cardiff To Pursue Narrower CRC Market For Onvansertib As Top Execs Step Down - Citeline News & Insights
Cardiff Oncology Overhauls Leadership to Advance Onvansertib - TipRanks
Favorite son in PLK1? Cardiff dips as phase II CRC bid advances - bioworld.com
CEO transition at Cardiff Oncology (NASDAQ: CRDF) paired with positive Phase 2 trial - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Cardiff Oncology (CRDF) Shares Plunge After Executive Departures and Trial Update - GuruFocus
Cardiff Oncology Shares Plunge 35% Following CEO and CFO Resignations - Intellectia AI
Cardiff Oncology Sees Unusually Large Options Volume (NASDAQ:CRDF) - MarketBeat
Cardiff Oncology Taps Interim CEO, Picks 30mg Onvansertib Regimen for 2026 Registrational mCRC Study - MarketBeat
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development - The Globe and Mail
Cardiff Oncology down after leadership shakeup (CRDF:NASDAQ) - Seeking Alpha
Cardiff Oncology stock tumbles after Phase 2 trial data update By Investing.com - Investing.com Canada
Cardiff Oncology plunges after top executives step down - TradingView
Cardiff Oncology (CRDF) Reports Promising Phase 2 Trial Results - GuruFocus
Cardiff Oncology reports positive phase 2 data for cancer drug - Investing.com
Cardiff Oncology reports positive phase 2 data for cancer drug By Investing.com - Investing.com Nigeria
Cardiff Oncology (CRDF) Announces Leadership Changes - GuruFocus
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC - The Manila Times
Cardiff Oncology Announces Positive Phase 2 Trial Results for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer - Quiver Quantitative
Cardiff Oncology Announces Positive Update from its - GlobeNewswire
Guidance Update: Can SPAR Group Inc generate free cash flowJuly 2025 Pullbacks & Real-Time Market Sentiment Reports - baoquankhu1.vn
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update - ADVFN
CRDFTrovagene Presents Outlook for Second Half of 2018 - ADVFN
CRDF Stock Price, Forecast & Analysis | CARDIFF ONCOLOGY INC (NASDAQ:CRDF) - Chartmill
3 Promising Penny Stocks With Market Caps Below $600M - simplywall.st
How Cardiff Oncology Inc. stock benefits from tech adoptionMorning Star Patterns & Free Long-Term Investment Planning - bollywoodhelpline.com
Gains Recap: Should you buy the dip on Cardiff Oncology Inc2025 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
Will Cardiff Oncology Inc. benefit from sector rotationJuly 2025 Snapshot & Safe Entry Trade Reports - bollywoodhelpline.com
What hedge fund moves indicate for Cardiff Oncology Inc. (XE7C) stock2025 Sector Review & Weekly Setup with ROI Potential - Bollywood Helpline
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $11.13 Consensus Price Target from Brokerages - Defense World
Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm (NASDAQ:CRDF) - Seeking Alpha
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is Cardiff Oncology Inc. stock a buy for dividend growthJuly 2025 Action & Long Hold Capital Preservation Tips - Улправда
Aug Wrap: How Cardiff Oncology Inc XE7C stock reacts to Fed tightening2025 Breakouts & Breakdowns & Fast Gain Stock Tips - Bộ Nội Vụ
How Cardiff Oncology Inc. (XE7C) stock reacts to Fed tighteningRisk Management & Stepwise Swing Trade Plans - Улправда
Finanzdaten der Cardiff Oncology Inc-Aktie (CRDF)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cardiff Oncology Inc-Aktie (CRDF) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
15,000 |
36,750 |
1,345,676 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):